SecProbe.io

CORRESP
1
filename1.htm

corresp1

November 9, 2006

VIA EDGAR AND FACSIMILE

    Emergent BioSolutions, Inc.

300 Professional Drive, Suite 250

Gaithersburg, MD 20879

    Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    t 301 944 0290

f 301 944 0173

www.emergentbiosolutions.com

Attention: Song P. Brandon, Esq.

    Re:

    Emergent BioSolutions Inc.

    Registration Statement on Form S-1

    File No. 333-136622

    Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Emergent BioSolutions Inc., a
Delaware corporation (the “Company”), hereby requests acceleration of the effective date of its
Registration Statement on Form S-1 (File No. 333-136622), as amended (the “Registration
Statement”), so that it may become effective at 5:00 p.m. Eastern time on November 14, 2006, or as
soon thereafter as practicable.

The Company hereby acknowledges that:

    (i)

    should the Securities and Exchange Commission (the “Commission”) or the staff, acting
pursuant to delegated authority, declare the Registration Statement effective, it does not
foreclose the Commission from taking any action with respect to the Registration Statement;

    (ii)

    the action of the Commission or the staff, acting pursuant to delegated authority, in
declaring the Registration Statement effective, does not relieve the Company from its full
responsibility for the adequacy and accuracy of the disclosure in the Registration Statement;
and

    iii)

    the Company may not assert staff comments and the declaration of
effectiveness of the Registration Statement as a defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.

    Very truly yours,

EMERGENT BIOSOLUTIONS INC.

    By:
    /s/ Daniel J. Abdun-Nabi

    Daniel J. Abdun-Nabi

    Senior Vice President Corporate Affairs,

General Counsel and Secretary